Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 3Terminated 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 78Prostatic Neoplasms 56Breast Neoplasms 49Lung Neoplasms 31Neoplasms 20Neoplasm Metastasis 18Stomach Neoplasms 14Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Recurrence 7Pancreatic Neoplasms 7Ovarian Neoplasms 7Adenocarcinoma of Lung 7Sarcoma 6Esophageal Neoplasms 6Carcinoma, Transitional Cell 5Carcinoma, Squamous Cell 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Triple Negative Breast Neoplasms 3Advanced Non-Small Cell Lung Cancer 3Adenocarcinoma, Bronchiolo-Alveolar 3Solid Tumor 2Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Inflammatory Breast Neoplasms 2Hormone Refractory Prostate Cancer 2HER2-positive Breast Cancer 2Fallopian Tube Neoplasms 2

Interventions

enzalutamide 4abiraterone 2Docetaxel 2tasquinimod 1sabizabulin 1olaparib 1ipatasertib 1darolutamide 1atezolizumab 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms, Castration-Resistant × Docetaxel × Clear all
NCT05169684 2025-06-10

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

Phase 2 Terminated
10 enrolled 15 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT04404140 2023-10-17

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Hoffmann-La Roche

Phase 1 Terminated
6 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡